Tokyo, Nov. 1 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000059198) titled 'A Retrospective Observational Study on Treatment Outcomes Following Switching to Anti-IL-5 Therapy in EGPA' on Nov. 1.
Study Type:
Observational
Primary Sponsor:
Institute - Saitama Medical University
Condition:
Condition - eosinophilic granulomatosis with polyangiitis: EGPA
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - Confirm the impact on treatment efficacy following changes in antibody therapy
Basic objectives2 - Efficacy
Eligibility:
Age-lower limit - 18
years-old
Gender - Male and Female
Key inclusion criteria - Patients undergoing anti-IL-5 antibody therapy for EGPA.
Patients who provided consent.
Key exclusion criteria - Patients who did not provide consent.
Target Size - 5
Recruitment Status:
Recruitment status - Preinitiation
Date of protocol fixation - 2025 Year 04 Month 01 Day
Anticipated trial start date - 2025 Year 04 Month 10 Day
Last follow-up date - 2028 Year 03 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000067705
Disclaimer: Curated by HT Syndication.
